JG
VRDN icon

Jefferies Group’s Viridian Therapeutics VRDN Stock Holding History

Jefferies Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$618K Buy
+30,110
New +$541K 0.01% 964
2018
Q4 		– Sell
-1,325
Closed -$111K – 2609
2018
Q3 		$111K Buy
1,325
+574
+76% +$54.1K ﹤0.01% 2206
2018
Q2 		$72K Buy
+751
New +$79.4K ﹤0.01% 2174

Other funds holding VRDN

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Group's VRDN Position: Q3 2022 in Review

Jefferies Group opened a new position in Viridian Therapeutics (VRDN) in Q3 2022: 30,110 shares worth $618K. The stake represents 0.01% of the portfolio and ranks #964 among its holdings. This is a return to the name: Jefferies Group previously reported a position in VRDN as recently as Q3 2018.

Jefferies Group first reported a position in VRDN in Q2 2018 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold VRDN as of Q3 2022.

  • Jefferies Group held 30,110 shares of Viridian Therapeutics worth $618K as of Q3 2022.
  • Viridian Therapeutics was a new Jefferies Group position in Q3 2022.
  • Viridian Therapeutics made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #964 holding.
  • Jefferies Group first reported a position in Viridian Therapeutics in Q2 2018 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.